Volume 3.11 | Mar 24

     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Neonatal NK Cell Repertoires Are Functionally But Not Structurally Biased Towards Recognition of Self HLA Class I
Researchers show that NK cell repertoires in cord blood are not yet shaped towards increased clonal frequencies of KIR for self-HLA class I as determined for the three major KIR ligands C1, C2, and Bw4. [Blood]

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Genome-Wide Promoter DNA Methylation Dynamics of Human Hematopoietic Progenitor Cells During Differentiation and Aging
Results provide detailed insight into the methylation dynamics during differentiation and suggest that epigenetic changes contribute to hematopoietic progenitor cell aging. [Blood]

Ex Vivo Expansion of Human Hematopoietic Stem and Progenitor Cells
Researchers review early attempts at ex vivo expansion by cytokine stimulation followed by an examination of their studies investigating the role of Notch signaling in hematopoietic stem and progenitor cell self-renewal. They also review other recently developed approaches for ex vivo expansion, primarily focused on the more extensively studied cord blood-derived stem cell. [Blood]

Evaluation of Senescence in Mesenchymal Stem Cells Isolated from Equine Bone Marrow, Adipose Tissue and Umbilical Cord Tissue
The purpose of this study was to compare the onset of replicative senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue and umbilical cord tissue. [Stem Cells Dev]

Variation in Management of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation
Researchers conducted a national survey of transplant physician members of the American Society for Blood and Marrow Transplantation to discern variation in immune suppression (IS) management, characterize the burden of GVHD emerging in the setting of IS taper, and describe the proportion of hematopoietic cell transplantation (HCT) recipients who successfully discontinue IS by 2 and 5 years post-HCT. [Biol Blood Marrow Transplant]

Cord Blood Stem Cell Banking: A Snapshot of the Italian Situation
Cord blood (CB) is a valuable community resource but expectant parents should be better informed as to the quality variables necessary for its storage, both by institutions and by professionals. Currently, most of the advertising is insufficient to justify the expense and the hopes pinned on autologous use of CB stem cells. [Transfusion]

Human CD8 T Cells Generated In Vitro from Hematopoietic Stem Cells Are Functionally Mature
Researchers addressed whether functional CD8 T cells can be generated fully in vitro using human umbilical cord blood hematopoietic stem cells in coculture with OP9-DL1 cells. [BMC Immunol]

CXC Chemokine Receptor 1 Enhances the Ability of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells to Migrate Toward Gliomas
Researchers showed that knocking-down interleukin-8 in glioma cells, or its receptor, CXC chemokine receptor 1 in human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) reduced hUCB-MSC migration toward glioma cells in a Transwell chamber. [Biochem Biophys Res Commun]

Donor Cell-Derived Leukemias/Myelodysplastic Neoplasms in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Analyzing the cases, pooled with reported cases, with survival models showed much shorter latency for malignancy as primary disease, for T-cell large granular lymphocyte leukemia as type of donor cell leukemia, and for umbilical cord blood as stem cell source. [Am J Clin Pathol]

Interleukin (IL)-15 in Combination with IL-2, fms-Like Tyrosine Kinase-3 Ligand and Anti-CD3 Significantly Enhances Umbilical Cord Blood Natural Killer (NK) Cell and NK-Cell Subset Expansion and NK Function
Researchers investigated the effects of short-term culture with anti-CD3 + IL-2 + FLT-3 + IL-15 on cord blood NK cell and NK-cell subset expansion and function. [Cytotherapy]

Transplanted Human Cord Blood-Derived Unrestricted Somatic Stem Cells Preserve High-Energy Reserves at the Site of Acute Myocardial Infarction
The concentration of ADP, ATP and creatinine phosphate in the marginal zone of the infarction was significantly higher in the human cord blood-derived unrestricted somatic stem cell group. [Cytotherapy]


National Cord Blood Program Files Biologics License Application with FDA
The National Cord Blood Program at New York Blood Center’s Howard P. Milstein National Cord Blood Center has submitted the first publicly-announced Biologics License Application for Cord Blood (Hematopoietic Progenitor Cells, Cord) to the Food and Drug Administration. [New York Blood Center Press Release]

Cellerant Therapeutics Initiates a Phase I/II Clinical Trial of CLT-008 for Chemotherapy Induced Neutropenia in Acute Leukemia Patients
Cellerant Therapeutics Inc. announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia. [Cellerant Therapeutics, Inc. Press Release]

Massachusetts Life Sciences Center Board Approves 2011 Accelerator Program Loans for Early-Stage Companies
The Massachusetts Life Sciences Center announced the awarding of $3.75 million in loans to five early-stage life sciences companies. [Massachusetts Life Sciences Center Press Release]

Pluristem to Develop Stem Cell Therapy on Its Own: CEO
Pluristem Therapeutics Inc. said it will go solo in developing its stem cell therapy to treat severe obstruction of arteries that can lead to amputation, but will look for a marketing partner to launch the therapy. [Reuters]

Strong Results: Revenue Up 5% to €40.4 Million and Operating Profit Up 92% to €4.5 Million
Cryo-Save Group N.V. has published its financial results for the year ended 31 December 2010. [Cryo-Save Group N.V. Press Release]

StemCyte Launches CordBloodTV
California-based StemCyte, Inc. announces the launch of www.cordbloodtv.com, a first-of-its-kind video cord blood banking education resource. [PR Newswire]

Cord Blood America Announces New Marketing Program
Cord Blood America, Inc. announced a new marketing affiliate program designed to educate and recruit professionals who interact with expectant parents during the later stages of pregnancy. [Cord Blood America, Inc. Press Release]
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.


Implementation Coordinator – Maternity Leave Contract (STEMSOFT Software Inc.)

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Supervisor Cell Therapy Laboratory – Cord Blood Bank (The University of Texas MD Anderson Cancer Center)

Supervisor Cell Therapy Lab (The University of Texas MD Anderson Cancer Center)

Cell Therapy Manufacturing Manager (Opexa Therapeutics)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us